Drug Companies Update December 2008
Mergers, acquisitions & Joint Ventures
- Ipsen has acquired Tercia. Tercia will remain a subsidiary.
- Ranbaxy has become a subsdiary of Daiichi Sankyo.
- ViroPharma has acquired Lev Pharmaceuticals.
New Companies
- Andromeda Biotech, a wholly-owned subsidiary of Clal Biotechnology Industries, is developing treatments for autoimmune diabetes.
- Archer Pharmaceuticals focuses on targeted drug discovery for Alzheimer's disease.
- China-based Botanic Century is engaged in the development of plant-based on traditional Chinese medicine for the treatment of a variety of diseases.
- Calabar AB is a privately-owned company that aims to develop xerostomia therapeutics.
- Celonic is engaged in the development of protein therapeutics for cancer and immune diseases.
- Circadian Technologies is an Australian biotechnology company focused on the development of biologic for the treatment of cancer and other serious human illnesses.
- EndGenitor develops stem cell therapies.
- Haemostatix focuses on the development of novel therapies for uncontrolled bleeding.
- Spanish company ISDIN develops compounds for skin pathologies.
- Kylin Therapeutics uses its RNAi technology for the treatment of a number of diseases including cancer.
- NeoBiocon develops biopharmaceuticals for diabetes, oncology, autoimmune disorders and cardiology.
- Neurok Pharma focuses on the development of virus-like particles for the treatment and prophylaxis of infectious diseases.
- Neumedicines is engaged in the research and development of prophylactics and therapeutics based on IL-12.
- Phoenix Biotechnology focuses on products from botanical extracts to treat cancer as a chronic illness.
- ProCell Therapeutics develops protein-based therapeutics capable of entering cells using intracellular transduction technologies.
- Recro Pharma develops and commercializes drugs for unmet medical needs, including pain and gastrointestinal disorders.
- SmartCells is developing SmartInsulin, a once-daily injectable insulin for the treatment of diabetes.
- Tetralogic is focused on the discovery and development of cancer therapeutics.
- Therosteon is a start-up developing compounds for bone diseases.
- Viamet Pharmaceuticals is developing small molecule inhibitors of metalloenzymes, using its Metallophile technology.
